Abstract
Molecules interfering with the Epidermal Growth Factor Receptor (EGFR) have been successfully tested in several human malignancies in the last decade, including non-small cell lung cancer, colo-rectal, pancreatic and head and neck cancer. Particularly, the two most commonly used strategies for blocking EGFR include tyrosine-kinase inhibitors (TKIs) targeting the intracellular domain of the receptor and monoclonal antibodies (MAb) directed against its external portion. One of main goals of researchers is to identify biological predictors of activity or resistance to these agents, both for ethical and pharmacoeconomical reasons. EGFR protein expression assessed by immunohistochemistry does not seem to accurately predict activity of either class of compounds, while presence of EGFR sensitizing mutations, which can be found in significant fractions of NSCLC patients, has been associated with a better outcome in patients receiving EGFR TKIs. Increased EGFR gene copy number could represent a reliable and reproducible tool for proper selection of patients candidate to TKIs or anti-EGFR MAbs. Furthermore, mechanisms of resistance to anti-EGFR strategies are currently being elucidated, allowing identification of subjects who should be excluded from treatment.
Keywords: EGFR, erlotinib, gefitinib, cetuximab, non-small cell lung cancer, colorectal cancer
Current Cancer Therapy Reviews
Title: Optimizing Anti-EGFR Strategies in Cancer Treatment
Volume: 3 Issue: 4
Author(s): Luca Toschi, Giovanna Finocchiaro, Isabella Garassino, Fabio De Vincenzo, Elisabetta Campagnoli, Giovanni Luca Ceresoli, Raffaele Cavina, Paolo Andrea Zucali, Armando Santoro and Federico Cappuzzo
Affiliation:
Keywords: EGFR, erlotinib, gefitinib, cetuximab, non-small cell lung cancer, colorectal cancer
Abstract: Molecules interfering with the Epidermal Growth Factor Receptor (EGFR) have been successfully tested in several human malignancies in the last decade, including non-small cell lung cancer, colo-rectal, pancreatic and head and neck cancer. Particularly, the two most commonly used strategies for blocking EGFR include tyrosine-kinase inhibitors (TKIs) targeting the intracellular domain of the receptor and monoclonal antibodies (MAb) directed against its external portion. One of main goals of researchers is to identify biological predictors of activity or resistance to these agents, both for ethical and pharmacoeconomical reasons. EGFR protein expression assessed by immunohistochemistry does not seem to accurately predict activity of either class of compounds, while presence of EGFR sensitizing mutations, which can be found in significant fractions of NSCLC patients, has been associated with a better outcome in patients receiving EGFR TKIs. Increased EGFR gene copy number could represent a reliable and reproducible tool for proper selection of patients candidate to TKIs or anti-EGFR MAbs. Furthermore, mechanisms of resistance to anti-EGFR strategies are currently being elucidated, allowing identification of subjects who should be excluded from treatment.
Export Options
About this article
Cite this article as:
Toschi Luca, Finocchiaro Giovanna, Garassino Isabella, Vincenzo De Fabio, Campagnoli Elisabetta, Ceresoli Luca Giovanni, Cavina Raffaele, Zucali Andrea Paolo, Santoro Armando and Cappuzzo Federico, Optimizing Anti-EGFR Strategies in Cancer Treatment, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782497059
DOI https://dx.doi.org/10.2174/157339407782497059 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Head and Neck Cancer: Recent Findings and New Targets
Current Topics in Medicinal Chemistry Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines
Current Molecular Pharmacology Enhanced Gene Delivery and/or Efficacy by Functional Peptide and Protein
Current Topics in Medicinal Chemistry Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Hematological Targets of Radiation Damage
Current Drug Targets Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Proteinases as Biomarkers in Breast Cancer Prognosis and Diagnosis
Mini-Reviews in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters An Update on JAK Inhibitors
Current Medicinal Chemistry Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Cyclooxygenase-2 Biology
Current Pharmaceutical Design